ProstaMine: a Bioinformatics Tool for Identifying Subtype-specific Co-alterations Associated with Aggressiveness in Prostate Cancer

Overview

Journal Front Pharmacol

Date 2024 May 16

PMID 38751776

Authors

Michael V Orman

Varsha Sreekanth

Teemu D Laajala

Scott D Cramer

James C Costello

Affiliations

Soon will be listed here.

Abstract

Background: Prostate cancer is a leading cause of cancer-related deaths among men, marked by heterogeneous clinical and molecular characteristics. The complexity of the molecular landscape necessitates tools for identifying multi-gene co-alteration patterns that are associated with aggressive disease. The identification of such gene sets will allow for deeper characterization of the processes underlying prostate cancer progression and potentially lead to novel strategies for treatment.

Methods: We developed ProstaMine to systematically identify co-alterations associated with aggressiveness in prostate cancer molecular subtypes defined by high-fidelity alterations in primary prostate cancer. ProstaMine integrates genomic, transcriptomic, and clinical data from five primary and one metastatic prostate cancer cohorts to prioritize co-alterations enriched in metastatic disease and associated with disease progression.

Results: Integrated analysis of primary tumors defined a set of 17 prostate cancer alterations associated with aggressive characteristics. We applied ProstaMine to loss and loss tumors and identified subtype-specific co-alterations associated with metastasis and biochemical relapse in these molecular subtypes. In -loss prostate cancer, ProstaMine identified novel subtype-specific co-alterations known to regulate prostate cancer signaling pathways including MAPK, NF-kB, p53, PI3K, and Sonic hedgehog. In -loss prostate cancer, ProstaMine identified novel subtype-specific co-alterations involved in p53, STAT6, and MHC class I antigen presentation. Co-alterations impacting autophagy were noted in both molecular subtypes.

Conclusion: ProstaMine is a method to systematically identify novel subtype-specific co-alterations associated with aggressive characteristics in prostate cancer. The results from ProstaMine provide insights into potential subtype-specific mechanisms of prostate cancer progression which can be formed into testable experimental hypotheses. ProstaMine is publicly available at: https://bioinformatics.cuanschutz.edu/prostamine.

References

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I . Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci U S A. 2019; 116(23):11428-11436. PMC: 6561293. DOI: 10.1073/pnas.1902651116. View

Sattler H, Lensch R, Rohde V, Zimmer E, Meese E, Bonkhoff H . Novel amplification unit at chromosome 3q25-q27 in human prostate cancer. Prostate. 2000; 45(3):207-15. DOI: 10.1002/1097-0045(20001101)45:3<207::aid-pros2>3.0.co;2-h. View

Hieronymus H, Iaquinta P, Wongvipat J, Gopalan A, Murali R, Mao N . Deletion of 3p13-14 locus spanning FOXP1 to SHQ1 cooperates with PTEN loss in prostate oncogenesis. Nat Commun. 2017; 8(1):1081. PMC: 5651901. DOI: 10.1038/s41467-017-01198-9. View

Liu D, Augello M, Grbesa I, Prandi D, Liu Y, Shoag J . Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancer. J Clin Invest. 2021; 131(10). PMC: 8121518. DOI: 10.1172/JCI147878. View

Abdulkadir S, Magee J, Peters T, Kaleem Z, Naughton C, Humphrey P . Conditional loss of Nkx3.1 in adult mice induces prostatic intraepithelial neoplasia. Mol Cell Biol. 2002; 22(5):1495-503. PMC: 134699. DOI: 10.1128/MCB.22.5.1495-1503.2002. View

Latil A, Cussenot O, Fournier G, Driouch K, Lidereau R . Loss of heterozygosity at chromosome 16q in prostate adenocarcinoma: identification of three independent regions. Cancer Res. 1997; 57(6):1058-62. View

Hieronymus H, Schultz N, Gopalan A, Carver B, Chang M, Xiao Y . Copy number alteration burden predicts prostate cancer relapse. Proc Natl Acad Sci U S A. 2014; 111(30):11139-44. PMC: 4121784. DOI: 10.1073/pnas.1411446111. View

Jillson L, Rider L, Rodrigues L, Romero L, Karimpour-Fard A, Nieto C . Loss Drives Enhanced Androgen Signaling and Independently Confers Risk of Recurrence in Prostate Cancer with Joint Loss of . Mol Cancer Res. 2021; 19(7):1123-1136. PMC: 8254790. DOI: 10.1158/1541-7786.MCR-20-0913. View

10.

Augello M, Liu D, Deonarine L, Robinson B, Huang D, Stelloo S . CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis. Cancer Cell. 2019; 35(4):603-617.e8. PMC: 6467783. DOI: 10.1016/j.ccell.2019.03.001. View

11.

Ormond D, Kleinschmidt-DeMasters B, Cavalcante D, Smith E, Cramer S, Lucia M . Prostatic adenocarcinoma CNS parenchymal and dural metastases: alterations in ERG, CHD1 and MAP3K7 expression. J Neurooncol. 2019; 142(2):319-325. PMC: 6958997. DOI: 10.1007/s11060-019-03099-x. View

12.

Gkretsi V, Kalli M, Efstathiades C, Papageorgis P, Papanikolaou V, Zacharia L . Depletion of Ras Suppressor-1 (RSU-1) promotes cell invasion of breast cancer cells through a compensatory upregulation of a truncated isoform. Sci Rep. 2019; 9(1):10050. PMC: 6624310. DOI: 10.1038/s41598-019-46575-0. View

13.

Alers J, Rochat J, Krijtenburg P, Hop W, Kranse R, Rosenberg C . Identification of genetic markers for prostatic cancer progression. Lab Invest. 2000; 80(6):931-42. DOI: 10.1038/labinvest.3780096. View

14.

Boyd L, Mao X, Lu Y . The complexity of prostate cancer: genomic alterations and heterogeneity. Nat Rev Urol. 2012; 9(11):652-64. DOI: 10.1038/nrurol.2012.185. View

15.

Ueda T, Komiya A, Suzuki H, Shimbo M, Sakamoto S, Imamoto T . Loss of heterozygosity on chromosome 2 in Japanese patients with prostate cancer. Prostate. 2005; 64(3):265-71. DOI: 10.1002/pros.20228. View

16.

Perner S, Demichelis F, Beroukhim R, Schmidt F, Mosquera J, Setlur S . TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res. 2006; 66(17):8337-41. DOI: 10.1158/0008-5472.CAN-06-1482. View

17.

Emmert-Buck M, Vocke C, Pozzatti R, Duray P, Jennings S, Florence C . Allelic loss on chromosome 8p12-21 in microdissected prostatic intraepithelial neoplasia. Cancer Res. 1995; 55(14):2959-62. View

18.

Rodrigues L, Rider L, Nieto C, Romero L, Karimpour-Fard A, Loda M . Coordinate loss of MAP3K7 and CHD1 promotes aggressive prostate cancer. Cancer Res. 2015; 75(6):1021-34. PMC: 4531265. DOI: 10.1158/0008-5472.CAN-14-1596. View

19.

Liu W, Ewing C, Chang B, Li T, Sun J, Turner A . Multiple genomic alterations on 21q22 predict various TMPRSS2/ERG fusion transcripts in human prostate cancers. Genes Chromosomes Cancer. 2007; 46(11):972-80. DOI: 10.1002/gcc.20482. View

20.

Verhagen P, Hermans K, Brok M, van Weerden W, Tilanus M, de Weger R . Deletion of chromosomal region 6q14-16 in prostate cancer. Int J Cancer. 2002; 102(2):142-7. DOI: 10.1002/ijc.10677. View